The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BBNX | N/A | N/A | N/A | +32% |
| S&P | +14.77% | +87.2% | +13.35% | +14% |
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analogue with a stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.
No news articles found for Beta Bionics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $27.25M | 63.1% |
| Gross Profit | $15.12M | 69.6% |
| Gross Margin | 55.48% | 2.1% |
| Market Cap | $863.75M | 0.0% |
| Market Cap / Employee | $2.11M | 0.0% |
| Employees | 409 | 46.6% |
| Net Income | -$14,209.00K | -45.9% |
| EBITDA | -$16,360.00K | -57.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $38.49M | 120.2% |
| Accounts Receivable | $11.54M | 54.6% |
| Inventory | 20.4 | 80.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $5.71M | -2.5% |
| Short Term Debt | $1.98M | 36.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -36.46% | 0.0% |
| Return On Invested Capital | -179.78% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$10,011.00K | 13.2% |
| Operating Free Cash Flow | -$8,729.00K | 9.2% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change | |
|---|---|---|---|---|---|
| Price to Book | -2.16 | 2.01 | 2.86 | - | |
| Price to Sales | 7.60 | 8.11 | 9.79 | - | |
| Price to Tangible Book Value | -2.16 | 2.01 | 2.86 | - | |
| Enterprise Value to EBITDA | -16.97 | -20.28 | -39.49 | - | |
| Return on Equity | -81.3% | -47.5% | - | ||
| Total Debt | $7.26M | $6.97M | $6.69M | $7.69M | 5.29% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
